Submit a manuscript Sign up for article alerts Contact us

Instructions for authors

Meeting reports

See 'About this journal' for descriptions of different article types and information about policies and the refereeing process.


Meeting reports should focus on the key developments presented and discussed at the meeting and are intended to rely largely on the work described at the meeting, rather than being fully referenced accounts of a field.

For particularly large meetings it is preferable that more in-depth information is given on a few selected topics, rather than a brief account of absolutely everything presented. The main content of the Meeting reports should focus on new research discoveries and the application of this knowledge.

Meeting reports are usually commissioned but reports and suggestions may also be submitted for the editors' consideration.

Submission process

Manuscripts must be submitted by one of the authors of the manuscript, and should not be submitted by anyone on their behalf. The submitting author takes responsibility for the article during submission.

To facilitate rapid publication and to minimize administrative costs, Stem Cell Research & Therapy accepts only online submission.

Files can be submitted as a batch, or one by one. The submission process can be interrupted at any time; when users return to the site, they can carry on where they left off.

See below for examples of word processor and graphics file formats that can be accepted for the main manuscript document by the online submission system.

During submission you will be asked to provide a cover letter. Use this to explain why your manuscript should be published in the journal, to elaborate on any issues relating to our editorial policies in the 'About Stem Cell Research & Therapy' page, and to declare any potential competing interests.

Assistance with the process of manuscript preparation and submission is available from BioMed Central customer support team.

We also provide a collection of links to useful tools and resources for scientific authors on our Useful Tools page.

File formats

The following word processor file formats are acceptable for the main manuscript document:

TeX/LaTeX users: Please use BioMed Central's TeX template and BibTeX stylefile if you use TeX format. During the TeX submission process, please submit your TeX file as the main manuscript file and your bib/bbl file as a dependent file. Please also convert your TeX file into a PDF and submit this PDF as an additional file with the name 'Reference PDF'. This PDF will be used by internal staff as a reference point to check the layout of the article as the author intended. Please also note that all figures must be coded at the end of the TeX file and not inline.

If you have used another template for your manuscript, or if you do not wish to use BibTeX, then please submit your manuscript as a DVI file. We do not recommend converting to RTF.

For all TeX submissions, all relevant editable source must be submitted during the submission process. Failing to submit these source files will cause unnecessary delays in the publication procedures.

Preparing main manuscript text

General guidelines of the journal's style and language are given below.

Length of article

Meeting reports should be between 600 to 1200 words.

Overview of manuscript sections for Meeting reports

Manuscripts for Meeting reports submitted to should be divided into the following sections (in this order):

The Accession Numbers of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript should be provided, in square brackets and include the corresponding database name; for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116].

The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database (EMBL), DNA Data Bank of Japan (DDBJ), GenBank at the NCBI (GenBank), Protein Data Bank (PDB), Protein Information Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot).

Note that there should not be a reference list, and references are to be avoided (the odd one can be cited in the text if it is essential and describes work from labs other than those cited for giving talks at the meeting). If abstracts from the meeting are published in print or on the web, a single reference / link should be given to where they can be found, usually as the meeting is first mentioned, in the forms

  • 'the 39th annual meeting of the American Society for Cell Biology, Washington DC, December 11-15, 1999 (abstracts are freely available online [])'
  • 'the 39th annual meeting of the American Society for Cell Biology, Washington DC, December 11-15, 1999 (abstracts published in a Supplement to Molecular Biology of the Cell 1999)'

Title page

This should list the title of the article, the full names, institutional addresses and email addresses for all authors. The corresponding author should also be indicated.


A short, unstructured, single paragraph of 25-40 words giving an indication of the meeting on which the report is based; if it is based on one symposium at a big meeting, say so here. On first mention the meeting should be referred to in the style 'the 39th annual meeting of the American Society for Cell Biology, Washington DC, December 11-15, 1999'.


Three to ten keywords representing the main content of the article.

Main text

This should contain the body of the article, and may be broken into subsections with short, informative headings. Headings should describe the section contents but there should be no more than four in an article.

For each speaker mentioned, it is important to provide their full name, institute/company and country. Speakers should be referred to in one of the following ways:

  • David Botstein (Stanford University Medical School, USA) emphasized the importance of...
  • As detailed by Gerry Rubin (University of California Berkeley, USA)...
  • is under way at the European Molecular Biology Laboratory (poster presented by Pierre Gönczy)

On second mention, the speaker becomes just 'Botstein' (no first name, no affiliation).

The text should not contain information about the lecture hall, food, weather or other non-scientific matters.

If 'earlier' work is referred to, whether or not it has been published, it should simply be referred to as 'published work from the lab of Tom Pollard (The Salk Institute)', or 'Botstein's earlier work', according to whether or not the author of the earlier work has been mentioned already.

If the report author mentions their own talk, or work they were involved in, they should use 'I' or 'we', rather than the disingenuous 'Author X reported'

List of abbreviations

If abbreviations are used in the text they should be defined in the text at first use, and a list of abbreviations can be provided, which should precede the competing interests and authors' contributions.

Competing interests

A competing interest exists when your interpretation of data or presentation of information may be influenced by your personal or financial relationship with other people or organizations. Authors must disclose any financial competing interests; they should also reveal any non-financial competing interests that may cause them embarrassment were they to become public after the publication of the manuscript.

Authors are required to complete a declaration of competing interests. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.

When completing your declaration, please consider the following questions:

Financial competing interests

  • In the past five years have you received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? Is such an organization financing this manuscript (including the article-processing charge)? If so, please specify.
  • Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? If so, please specify.
  • Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript? If so, please specify.
  • Do you have any other financial competing interests? If so, please specify.

Non-financial competing interests

Are there any non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript? If so, please specify.

If you are unsure as to whether you, or one your co-authors, has a competing interest please discuss it with the editorial office.


Please acknowledge anyone who contributed towards the article by making substantial contributions to conception, design, acquisition of data, or analysis and interpretation of data, or who was involved in drafting the manuscript or revising it critically for important intellectual content, but who does not meet the criteria for authorship. Please also include the source(s) of funding for each author, and for the manuscript preparation. Authors must describe the role of the funding body, if any, in design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. Please also acknowledge anyone who contributed materials essential for the study. If a language editor has made significant revision of the manuscript, we recommend that you acknowledge the editor by name, where possible.

The role of a scientific (medical) writer must be included in the acknowledgements section, including their source(s) of funding. We suggest wording such as 'We thank Jane Doe who provided medical writing services on behalf of XYZ Pharmaceuticals Ltd.'

Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements section.


Endnotes should be designated within the text using a superscript lowercase letter and all notes (along with their corresponding letter) should be included in the Endnotes section. Please format this section in a paragraph rather than a list.